Welcome to our dedicated page for Red Light Hollan news (Ticker: TRUFF), a resource for investors and traders seeking the latest updates and insights on Red Light Hollan stock.
Red Light Holland Corp (TRUFF) generates news across functional mushrooms, psilocybin truffles, retail distribution, research collaborations, and treasury strategy. The company describes itself as an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal recreational market within the Netherlands, in compliance with all applicable laws.
News updates frequently cover financial and operational results, where Red Light Holland reports on cash balances, revenue trends, and performance of its various business units. These releases often include commentary on management’s priorities, such as streamlining operations, evaluating non-core assets, and exploring mergers and acquisitions that could support its mushroom and psilocybin-related activities.
Another major news theme is research and development in psilocybin. Articles detail the company’s partnership with Irvine Labs Inc., an FDA-compliant and DEA-registered facility in California, including shipments of naturally occurring psilocybin truffles from the Netherlands under United States Controlled Substances import permits, potency testing, Certificates of Analysis, and work on proprietary dehydration and packaging processes. Updates also highlight collaborations like the Psychedelic Genome Project at Arizona State University and the appointment of a scientific advisor in psychedelic neuroscience.
Red Light Holland news also follows consumer and retail milestones, such as Happy Caps Mushroom Farm’s expansion into Safeway stores in Oregon and Washington State, seasonal retail programs, and the launch of functional mushroom gummies on Amazon and in Canadian supermarkets. Additional coverage addresses the company’s Bitcoin balance sheet strategy, including purchases of Bitcoin exchange-traded fund shares and work with cryptocurrency advisors.
Investors and observers can use the TRUFF news feed to review earnings announcements, R&D progress, retail distribution developments, and strategic updates as the company reports them.
Red Light Holland (OTCQB: TRUFF) announced an intended corporate rebrand following the closing of the Filament Health acquisition and said a new name will be proposed at the Annual General and Special Meeting on May 11, 2026.
The combined company adds GMP manufacturing, FDA-aligned drug development capabilities and a lead botanical psilocybin candidate, PEX010, currently evaluated at >70 clinical research sites. Management urged shareholders to vote IN FAVOUR of the name-change resolution; details will be in the management information circular.
Red Light Holland (OTCQB: TRUFF) completed its acquisition of Filament Health effective April 29, 2026, creating a vertically integrated psychedelic platform combining Filament's pharmaceutical-grade R&D, a Health Canada Dealer's License, and a portfolio of 70+ patents with Red Light's global distribution.
The transaction issued 99,180,497 consideration shares plus 70,836,683 shares for debt settlement, leaving 595,727,901 Red Light shares outstanding and former Filament holders owning approximately 30%.
Red Light Holland (OTCQB: TRUFF) and Filament Health (OTC: FLHLF) announced that the Supreme Court of British Columbia issued a final order approving Red Light's planned acquisition of all issued and outstanding common shares of Filament under a statutory plan of arrangement.
Completion remains subject to customary conditions and certain regulatory approvals and is anticipated on or about April 29, 2026 under the arrangement agreement dated March 10, 2026. Further details are available in Filament's management information circular and on SEDAR+.
Red Light Holland (OTCQB: TRUFF) announced that Filament Health shareholders approved a plan of arrangement on April 24, 2026, enabling Red Light to acquire all issued Filament shares.
Key facts: 196,282,175 votes (≈99.99%) supported the arrangement; up to 182,447,452 Consideration Shares are issuable; Filament holders expected to own ≈30% post-close. Closing remains subject to court approval and customary conditions, with an expected close on or about April 29, 2026. Resale restrictions release 50% at six months, 25% at nine months and 25% at twelve months.
Red Light Holland (OTCQB: TRUFF) reports continued clinical shipments of Filament Health's botanical psilocybin drug candidate PEX010 to Canadian universities, including second shipments to University of Calgary and first-time shipments to University of British Columbia and additional UCalgary studies.
The company cites growing demand for pharmaceutical-grade natural psilocybin and notes a definitive arrangement agreement to acquire Filament Health, with an interim Supreme Court of British Columbia order issued March 23, 2026; closing remains subject to shareholder and final court approval and other customary conditions.
Red Light Holland (OTCQB:TRUFF) highlighted an FDA IND–authorized Phase 1 study led at the University of Washington showing that a second psilocybin session produced sustained psychological benefits in metastatic cancer patients.
Key data: mean HADS fell from 15.08 to 9.00 after the second session, 69% of participants dropped below clinical anxiety/depression thresholds, and reports of complete mystical experience rose from 38% to 77%. No serious adverse events reported. Filament's PEX010 now supplied to 70+ clinical sites worldwide. Red Light is promoting this evidence amid its proposed acquisition of Filament and evolving U.S. policy support for psychedelic research.
Red Light Holland (OTCQB:TRUFF) reported that Filament Health signed three new license agreements and completed two research shipments in March 2026, expanding PEX010 clinical research across Australia, the United Kingdom and Canada.
The company disclosed a definitive arrangement to acquire Filament, an interim Supreme Court of British Columbia order on March 23, 2026, and that PEX010 has clinical trial authorizations from Health Canada, the U.S. FDA and 10 other jurisdictions.
Red Light Holland (OTCQB: TRUFF) said it will support UCSF's Carhart-Harris Lab Global Psychedelic Study by directing researchers and clinicians receiving Filament Health's psilocybin candidate PEX010 on how to join the large-scale online study.
Filament has supplied PEX010 to over 70 trials worldwide and is authorized for use in several federally authorized compassionate use programs.
Red Light Holland (OTCQB: TRUFF) and Filament Health (OTC: FLHLF) received an Interim Order from the Supreme Court of British Columbia advancing Red Light's proposed statutory plan of arrangement to acquire Filament.
The order authorizes a Filament shareholder meeting on April 24, 2026; Filament's board unanimously recommends approval. Filament shareholders of record on March 2, 2026 may vote. Completion remains subject to shareholder, court and regulatory approvals.
Red Light Holland (OTCQB:TRUFF) engaged Kala Bio's Researgency.ai to support clinical development of Filament Health's patented botanical psilocybin candidate PEX010.
The company announced a definitive arrangement to acquire Filament's business, including 76 issued patents across 15 families, noted PEX010 has Health Canada and FDA trial authorizations, positive Phase 2 data in alcohol use disorder, and supply to >70 clinical sites.